Almac

INFα2b

• 165 aa residues – 2 disulphide bridges
• PEG-Intron® (Schering Plough) has been approved to treatment of Hepatitis C:
  • non-selective PEGylation (12 kDa linear)
  • 14 PEG positional isomers
  • in vitro antiviral activity is 28% of non-modified form

Click on image to enlarge

 

INFβ1b

• 165 aa residues – 1 disulphide bridge
• No PEGylated INFβ1b approved
• Rapid clearance from blood stream – frequent administration required
• Neutralizing Abs form in 45% of patients
• Physical instability

Click on image to enlarge